PERSEUS Trial Outcome Analysis

EP: 1.Unmet Needs and Standards of Care in Multiple Myeloma

EP: 2.A Unique Drug Delivery Technology for MM

EP: 3.PERSEUS Trial Design and Overview

Now Viewing

EP: 4.PERSEUS Trial Outcome Analysis

EP: 5.PERSEUS Trial Adverse Events and Safety Profiles

EP: 6.Integrating New Approaches to MM Treatment

EP: 7.Closing Perspectives on MM Treatment and Care

Summary

Brea C. Lipe, MD reviews the phase three randomized trial conducted by the European Myeloma Network compared induction therapy with Dara-VRd (daratumumab, lenalidomide, bortezomib, dexamethasone) versus VRd alone. The primary endpoint was progression-free survival. After a median follow-up of ~48 months, the 4-year PFS was significantly higher in the Dara-VRd arm at 84.7% vs 67.7% withVRD alone. The Dara-VRD arm also demonstrated improved depth of response, with higher rates of MRD negativity at multiple timepoints. This benefit with Dara-VRd was seen across most subpopulations, including high-risk patients. One exception was in older patients where there were too few patients and events to show a difference. Overall, the addition of daratumumab led to deeper responses and improved PFS. After transplantation, patients received 2 cycles of consolidation then went on lenalidomide maintenance, with the Dara- VRd arm receiving Dara-lenalidomide. Those who were MRD negative for 12+ months after 2 years could discontinue treatment. In summary, this robust trial provides evidence that adding daratumumab to standard induction/consolidation improves outcomes in eligible NDMM patients.

Summary was AI-generated and edited for clarity.